Białkomocz i upośledzenie funkcji nerek jako czynniki ryzyka sercowo-naczyniowego u chorych na cukrzycę
Piśmiennictwo
1. Moczulski D., Krolewski A.
Poszukiwanie genów dla nefropatii cukrzycowej. Nefrol. Dial. Pol. 2000;4:5‑9
2. Stenvinkel P., Carrero J.J., Axellson J. et al. Emerging
biomarkers for evaluating cardiovascular risk in chronic kidney disease
patient: how do new pieces fit into the uremic puzzle?
Clin. J. Am. Soc. Nephrol. 2008;3:505‑521
3. Czekalski S.
Microalbuminuria as a reversible marker of kidney and vascular damage.
Nephrol. Dial. Pol. 2006;10:166‑168
4. Czekalski S.
How to diagnose and how to interpret microalbuminuria in the diabetic patient?
Nephrol. Dial. Transplant. 1996;11:1509‑1511
5. Czekalski S. Nefropatia cukrzycowa czy cukrzycowa choroba nerek? Forum Nefrologiczne. 2008.
Tom 1, nr 2;53‑56
6. Forman J.P.,
Brenner B.M. 'Hypertension' and 'microalbuminuria': the bell tolls for
thee. Kidney Int. 2006;69(1):22‑28
7. Klausen K.P.,
Scharling H., Jensen G. et al. New definition of microalbuminuria in
hypertensive subjects: association with incident coronary heart disease and
death. Hypertension. 2005;46(1):33‑37
8. KDOQI Clinical Practice Guidelines and Clinical
Practice Recommendations for Diabetes and Chronic Kidney Disease. Am. J. Kidney Dis. 2007;49(supl.2):S1–S245
9. Verhave J.C.,
Gansevoort R.T., Hillege H.L. et al. An elevated urinary albumin
excretion predicts de novo development of renal function impairment in the
general population. Kidney Int. Suppl. 2004;92:S18‑21
10. Messent J.W.,
Elliott T.G., Hill R.D. et al. Prognostic significance of
microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three
year follow-up study. Kidney Int. 1992;41(4):836‑9
11. Rossing P.,
Hougaard P., Borch-Johnsen K. et al. Predictors of mortality in insulin
dependent diabetes: 10 year observational follow up study. BMJ.
1996;313(7060):779‑784
12. Gerstein H.C.,
Mann J.F., Yi Q. et al. Albuminuria and risk of cardiovascular
events, death, and heart failure in diabetic and nondiabetic individuals. JAMA
2001;286:421‑426
13. Niskanen L.,
Uusitupa M., Sarlund H. et al. Microalbuminuria predicts the
development of serum lipoprotein abnormalities favouring atherogenesis in newly
diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabetologia.
1990;33(4):237‑43
14. Gall M.A.,
Rossing P., Skøtt P. et al. Prevalence of micro- and
macroalbuminuria, arterial hypertension, retinopathy and large vessel disease
in European type 2 (non-insulin-dependent) diabetic patients.
Diabetologia. 1991;34(9):655‑61
15. Stuveling E.M.,
Bakker S.J., Hillege H.L. et al. C-reactive protein modifies the
relationship between blood pressure and microalbuminuria. Hypertension.
2004;43(4):791‑6
16. Asselbergs F.W.,
de Boer R.A., Diercks G.F. et al. Vascular endothelial growth
factor: the link between cardiovascular risk factors and microalbuminuria?
Int. J. Cardiol. 2004;93(2-3):211‑5
17. Stehouwer C.,
Smulders Y. Microalbuminuria and risk for cardiovascular disease: analysis
of potential mechanisms J. Am. Soc. Nephrol. 2006;17:2106‑2111
18. Czekalski S. Jak chronić nerki i serce
u chorych na cukrzycę i kiedy rozpocząć leczenie nerkozastępcze? Przew. Lek. 2007;1:46‑52
19. Effects
of ramipril on cardiovascular and microvascular outcomes in people with
diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart
Outcomes Prevention Evaluation Study Investigators. Lancet. 2000;355(9200):253‑259
20. Eijkelkamp W.,
Zhang Z., Remuzzi G. et al. Albuminuria is a target for renoprotective
therapy independent from blood pressure in patients with type 2 diabetic
nephropathy: post hoc analysis from the reduction of endpoints in NIDDM with
the angiotensin II antagonist losartan (RENAAL) trial.
J. Am. Soc. Nephrol. 2007;18:1540‑1546
21. Jennings D.L.,
Kalaus J.S., Coleman C.I.
et al. Combination therapy with an ACE inhibitor and an angiotensin
receptor blocker for diabetic nephropathy: a meta-analysis. Diabet. Med.
2007;24(5):486‑493
22. Düsing R.,
Sellers F. ACE inhibitors, angiotensin receptor blockers and direct renin
inhibitors in combination: a review of their role after the ONTARGET
trial. Curr. Med. Res. Opin. 2009;25(9):2287‑2301
23. Mann J.F.,
Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or
both, in people at high vascular risk (the ONTARGET study): a multicentre,
randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547‑553
24. Gaede P.,
Vedel P., Larsen N. et al. Multifactorial intervention and cardiovascular
disease in patients with type 2 diabetes. N. Engl. J. Med.
2003;348(5):383‑393
25. Mann J.F.,
Gerstein H.C., Pogue J. et al. Renal insufficiency as a predictor of
cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.
Ann Intern Med. 2001;134(8):629‑636
26. Ibsen H.,
Wachtell K., Olsen M.H. et al. Albuminuria and cardiovascular risk in
hypertensive patients with left ventricular hypertrophy: the LIFE Study. Kidney
Int. Suppl. 2004;(92):S56‑8
27. Kaplan N.M. Management of
hypertension in patients with type 2 diabetes mellitus: guidelines based
on current evidence. Ann. Intern. Med. 2001;135(12):1079‑83
28. Oko A.,
Pawlaczyk K., Czekalski S. Leczenie nadciśnienia współistniejącego
z cukrzycą. Przew. Lek. 2003;6(1):125‑131
29. Czekalski S.
Optymalizacja leczenia cukrzycowej choroby nerek Przew. Lek. 2009;5:41‑46
30. Sato A.,
Hayaski K., Naruse M. et al. Effectiveness of aldosterone blockade in
patients with diabetic nephropathy. Hypertension. 2003;41:64‑68
31. Kang K.S.,
Ko G.J., Lee M.H. et al. Effect of eplerenone, enalapril and their
combination treatment on diabetic nephropathy in type II diabetic rats.
Nephrol. Dial. Transplant. 2009;24(1):73‑84
32. Parving H, Persson F,
Lewis J. Aliskiren combined with losartan in type 2 diabetes and
nephropathy. N. Engl. J. Med. 2008;358(23):2433‑2446
33. Matuszkiewicz-Rowińska J.
Kontrowersje na temat zespołu niedożywienie, zapalenie, miażdżyca (MIA)
w przewlekłej niewydolności nerek. Nefrol. Dial. Pol. 2006;10:88‑90
34. Vanholder R.,
Massy Z., Argiles A. et al. Chronic kidney disease as cause of
cardiovascular morbidity and mortality. Nephrol Dial Transplant.
2005;20(6):1048‑1056
35. Levin A.,
Singer J., Thompson C.R. et al. Prevalent left ventricular
hypertrophy in the predialysis population: identifying opportunities for
intervention. Am. J. Kidney Dis. 1996;3:347‑354
36. Zhang L.,
Zhao F. Yang Y. et al. Association between carotid artery intima-
media thickness and early-stage CKD in a Chinese population.
Am. J. Kidney Dis. 2007;49(6):786‑792
37. Gaede P.,
Vedel P., Parving H.H. et al. Intensified multifactorial intervention
in patients with type 2 diabetes mellitus and microalbuminuria: the Steno
type 2 randomised study. Lancet. 1999;353(9153):617‑622
